Can tailored nanoceria act as a prebiotic? Report on improved lipid profile and gut microbiota in obese mice
Autor: | Olga Golubnitschaja, Mykola Ya Spivak, Rostyslav V Bubnov, M. V. Kryvtsova, Oleksandr B. Shcherbakov, Liudmyla M Lazarenko, Nadiya M. Zholobak, L. P. Babenko |
---|---|
Rok vydání: | 2019 |
Předmět: |
0301 basic medicine
medicine.medical_treatment Gut flora Pharmacology law.invention 03 medical and health sciences Probiotic 0302 clinical medicine Blood serum law Oral administration Lactobacillus Drug Discovery Medicine Microbiome Bifidobacterium biology business.industry Health Policy Prebiotic Research Biochemistry (medical) biology.organism_classification 030104 developmental biology 030220 oncology & carcinogenesis business |
Zdroj: | EPMA J |
ISSN: | 1878-5077 |
Popis: | BACKGROUND: Microbiome modulation is a pillar intervention to treat metabolic syndrome, prestages, and cascade of related pathologies such as atherosclerosis, among others. Lactobacillus and Bifidobacterium probiotic strains demonstrate efficacy to reduce obesity, dyslipidemia, and improve metabolic health. Novel prebiotic substances composed with known probiotics may strongly synergize health benefits to the host. The aim of this study was to evaluate beneficial effects of Lactobacillus and Bifidobacterium strains (probiotics) if composed with nanoceria (potential prebiotic) to reduce cholesterol levels and restore gut microbiota in obese mice. MATERIALS AND METHODS: Two lines of mice were used in the study: BALB/c mice (6–8 weeks, 18–24 g) and CBA mice (11–12 months, 20–26 g); experimental animals were fed by fat-enriched diet 3 weeks before the evaluation. Animals were divided into groups to test probiotic strains and nanoceria. All groups received probiotic strains orally and cerium dioxide orally or intravenously in various composition. A group of untreated animals was used as a control. Cholesterol level and gut microbiota of mice were studied. RESULTS: Cerium dioxide nanoparticles, probiotic strain L. casei ІМV В-7280, and composition B. animalis VKB/B. animalis VKL applied separately and in different combinations all reduced at different levels free and bound cholesterol in blood serum of mice fed by fat-enriched diet. The combination of 0.01 M nanoceria and probiotic strain L. casei ІМV В-7280 resulted in the fastest cholesterol level decrease in both young and mature animals. Oral administration of CeO(2) applied alone reduced the number of microscopic fungi in the gut of mice and Gram-positive cocci (staphylococci and/or streptococci). Application of L. casei IMV B-7280 as a probiotic strain increased most significantly the number of lactobacilli and bifidobacteria in the gut of mice. The most significant normalization of gut microbiota was observed after oral administration of alternatively either L. casei IMV B-7280 + 0.1 M CeO(2) or L. casei IMV B-7280 + 0.01 M CeO(2). CONCLUSION: Dietary application of nanoceria combined with probiotic strains L. casei IMV B-7280, B. animalis VKB, and B. animals VKL has significantly reduced both free and bound cholesterol levels in serum. Simultaneous administration of probiotics and cerium nanoparticles as a prebiotic, in various combinations, significantly enhanced positive individual effects of them on the gut microbiota spectrum. The presented results provide novel insights into mechanisms behind nutritional supplements and open new perspectives for application of probiotics combined with substances demonstrating prebiotic qualities benefiting, therefore, the host health. Follow-up translational measures are discussed to bring new knowledge from lab to the patient. If validated in a large-scale clinical study, this approach might be instrumental for primary and secondary prevention in obese individual and patients diagnosed with diabetes. To this end, individualized prediction and treatments tailored to the person are strongly recommended to benefit the health condition of affected individuals. |
Databáze: | OpenAIRE |
Externí odkaz: |